Abstract Halstoctacoanolides A and B are 28-membered polyketide macrolactones and were isolated from Streptomyces halstedii HC34. The biosynthetic gene cluster (hls cluster) of halstoctacosanolides was completely identified from the genome library of Streptomyces halstedii HC34. DNA sequence analysis of ca. 100 kb region revealed that there were seven type I polyketide synthases (PKSs) and two cytochrome P450 monooxygenases in this cluster. Involvement of the gene cluster in the halstoctacosanolide biosynthesis was demonstrated by the gene disruption of P450 monooxygenase genes. The mutants produced a new deoxygenated halstoctacosanolide derivative, halstoctacosanolide C, which confirmed that the hls gene cluster was essential for the biosynthesis of halstoctacosanolides.
Introduction
Polyketide macrolides are one of the largest bioactive natural product families. They have various complex structures and a huge variety of bioactivities have been reported for them. Three examples are the antibiotic erythromycin, immunosuppressant rapamycin and the antitumor agent epothilone, and there are many other polyketide macrolides that are clinically important [1] . Polyketide chains are generally biosynthesized in a similar manner by the multi-modular enzymes, type I polyketide synthases (PKSs) [1] . Each module is responsible for one elongation of an extender unit and modification of the bcarbon by coordinated domains. In generally, the polyketide structures well reflect the domain structure of its own biosynthetic PKSs. Because these domain structures are easily assigned from the gene information, it is now possible to predict the polyketide structure biosynthesized by PKSs when once the DNA sequences of the genes encoding PKSs are determined. Based on this context, the predictions of the polyketide productivity and the searches of new polyketide compounds from organisms having the PKS genes, especially from the major secondary metabolite producer actinomycetes, have been accomplished [2ϳ6] . Molecular genetic studies of the actinomycetes, thus, present promising opportunities for the discovery of a new polyketide compound potentially useful for drug development.
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Halstocacosanides A and B are polyketides which have a 28-membered macrolactone structure and were discovered in the genome of Streptomyces halstedii HC34 using the strategy outlined in the previous paragraph. Subsequent isolation and evaluation of these compounds demonstrated that they possess moderate antimicrobial activity against several microorganisms [3] . However, the complete gene cluster had not been cloned. To confirm the complete biosynthetic gene cluster and in an effort to generate halstoctacosanolide analogues through genetic engineering, ca. 100 kb segment of DNA containing the putative halstoctacosanolide (hls) biosynthetic gene cluster from Streptomyces halstedii HC34 was cloned and sequenced. In this paper, we report the cloning and characterization of the complete gene cluster for halstoctacoanolide biosynthesis. Also described are isolation and structure determination of a new halstoctacosanolide derivative produced by gene disruption of cytochrome P450 monooxygenases in the hls cluster.
Results and Discussion

Cloning and Sequencing of Complete Halstoctacosanolide Biosynthetic Gene Cluster
Previously, three cosmids (7-4F, 3-8A and 10-10H) including total ca. 45 kb DNA sequence had been cloned for the halstoctacosanolide biosynthetic gene and the DNA sequence contain three open reading flames (ORFs) encoding PKS [3] . To identify the complete gene cluster, genomic walking using a S. halstedii HC34 genome library was curried out by standard hybridization method. Based on the known DNA sequences, DIG labeled probes were prepared for the hybridization. Using the sequence of most downstream region as a probe, the next overlapped cosmid was cloned. By repeating this procedure for several times, three cosmids (18-9Q, 22-5B and 22-7D) were newly identified, and ca. 60 kb of contiguous DNA was sequenced. There are nine ORFs in the whole hls cluster, which encode seven PKS genes and two cytochrome P450 monooxygenases as shown in Figure 2 . The DNA sequence has been deposited in the DNA Data Base of Japan (DDBJ) under the accession number AB241068. 
PKS Genes
There are seven PKS genes, hlsA to hlsG, containing eighty-eight catalytic domains organized into one loading and eighteen extender modules in a ca. 100 kb region of the hls gene cluster. The number of modules is same as the number of the extender units, which is required for the construction of halstoctacoanolides. These genes are arranged straight forwardly head to tail, and there is no gene encoding non-PKS as seen in the rifamycin biosynthetic gene cluster [7] . When the chain elongation reactions sequentially proceed from upstream to downstream, the PKS gene structures well reflect the structure of polyketide chain of halstoctacosanolides except for a ketonic moiety at C-17 and an acetal function at C-11 as shown in Figure 2 . These functional groups are presumably unreduced by the KR modules and remain in the carbonyl functions during the elongation steps by PKSs. However, since all modules contain KR domain, certain contradiction appeared between the gene structure and the chemical structure. Some inactive KR domains have been reported to lack the active site motif, GXGXXGXXXA for NADP-binding or the catalytic triad, Lys, Ser and Tyr in the active site [8] . However, in the case of hls KR, all the important amino acid residues appeared to be conserved in all KR. Although the exact reason is not clear at the moment, a similar case was reported in avermectin PKSs, module 10 [9] . Halstoctacoanolides A and B have one trisubstituted Z olefin at C-8 position. Usually, most of the double bond geometry found in polyketide chains is E-configuration. It has been suggested that the stereochemistry of b-hydroxyl group derived from KR domain might control the double bond geometry in DH domain [8] . An Asp residue of KR domain was proposed to be an important residue for determining the stereospecificity. However, in our case, the Asp residue is found in all KR domains by multiple alignments. It is known that there are a few exceptions to this hypothesis [10] , and in the hls gene cluster this is also not the case.
Two Genes Encoding Cytochrome P450
Halstoctacosanolide A has two additional oxygen functional groups (C-4 and C-32) rather than those derived from the usual PKSs chain elongation pathway, which are considered to be introduced after the polyketide chain elongation. Accordingly, it had been expected that there are several genes encoding the oxidation enzymes. In fact, two genes, hlsH and hlsI, were identified to encode cytochrome P450 monooxygenases in the downstream region of the PKS genes. In the rapamycin biosynthesis, the methylene group at C-9 of rapamycin polyketide chain was reported to be oxidized to the carbonyl group by a single cytochrome P450 enzyme, RapJ [11] . Therefore, it seemed likely that a single enzyme, either HlsH or HlsI, catalyzes the oxidation of methylene group at C-4 to carbonyl group, and another may be responsible for the hydroxylation at C-32. However, since the amino acid sequences of HlsH and HlsI are quite similar (identity 42%) and belong to the same CYP family CYP107 found in secondary metabolism [12, 13] , it was not easily predictable which enzyme is responsible to either of oxidations. Therefore, to determine the function of each gene, the gene disruption experiments were performed. Furthermore, the gene disruption experiments for these cytochrome P450 monooxygenases, hlsH and hlsI, could be expected to generate a new halstoctacosanolide analogue.
Disruptions of the Genes Encoding Cytochrome P450
The gene disruption experiments were carried out by gene insertional inactivation according to the previously reported method for the disruption of the vin genes in the same strain [14] . The apramycin resistant gene cassette was thus inserted into the AatII site that existed in hlsH and BamHI sites found in hlsI. Each fragment was subcloned into E. coli -Streptomyces shuttle vector pWHM3. The resulting plasmids were separately transformed into protoplasts of S. halstedii HC34 and the clones showing proper phenotype were selected. The gene disruptions of the resulting mutants, which showed apramycin resistance, were confirmed using Southern hybridization against BamHI fragments of S. halstedii genomic DNA, and the expected sizes of BamHI fragments (wild type; ca. 3.3 kb, hlsH mutant; ca. 4.6 kb, hlsI mutant; ca. 7.4 kb) appeared as shown in Figure 4 .
The fermentation broths of the wild type and two mutants were separately extracted with ethyl acetate, and the TLC analysis of the resulting extracts was performed as shown in Figure 5 . The hlsH mutant was found to lose the productivity of halstoctacosanolide A and to produce only halstoctacosanolide B. In the hlsI mutant, neither halstoctacosanolide A or B was produced at all. It should be noted that both mutants appeared to produce a new less polar compound. Thus, the isolation study of this compound was pursued.
Isolation and Structure Determination of a New Halstoctacosanolide Analogue
In the TLC analysis, the hlsI mutant seemed to produce a relatively large amount of the new compound. Thus, isolation study was carried out from the fermentation broth of the hlsI mutant according to the previous method for halstoctacosanolides [3] . Forty-two mg of the new compound, named halstoctacosanolide C, was successfully isolated from 1.5 liters culture. The physico-chemical properties of halstoctacosanolide C are summarized in In UV spectrum, the maximum absorption wavelength and the molar absorption coefficient were also quite similar to those of halstoctacosanolide B. However, the structure determination of halstoctacosanolide C was not straightforward because halstoctacosanolide C was obtained as an inseparable mixture of two components. The same phenomenon was observed in the case of halstoctacosanolide B, which suggested that halstoctacosanolide C also exists in an equilibrium of the hemiacetal and seco-ketone forms. Therefore, methyl 48 acetal derivatization was performed as in the case of halstoctacosanolide B. Thus, halstoctacosanolide C was treated with methanol under acidic condition and the methyl acetal derivative of halstoctacosanolide C was smoothly obtained. Since NMR spectra of methyl acetal derivative of halstoctacosanolide C at room temperature caused line broadening, all measurements were carried out at 50°C. 1 H and 13 C NMR spectra of methyl acetal derivative of halstoctacosanolide C were quite similar to those of methyl acetal derivative of halstoctacosanolide B except for disappearance of one oxymethine and appearance of one methylene (Table 3 ). Further analysis including 1 H-1 H COSY, HMQC and HMBC experiments established that halstoctacosanolide C is the C-32 deoxygenated derivative of halstoctacosanolide B.
These results clearly revealed the halstoctacosanolide biosynthetic pathway as follows. Firstly, seven PKSs (HlsA to G) generate halstoctacosanolide C from nine malonyl CoAs and ten methylmalonyl CoAs, and then the methylene group at C-32 is hydroxylated by HlsI to produce halstoctacosanolide B. Finally, halstoctacosanolide A is produced through oxidation of methylene group at C-4 of halstoctacosanolide B into carbonyl by HlsH as shown in Figure 6 . By the TLC experiments, the hlsH mutant appeared to produce halstoctacosanolide B with a small amount of halstoctacosanolide C. This may be due to a downstream polar effect caused by the gene disruption of hlsH, and the transcriptional disorder of the hlsI gene may be occurred.
In the present study, we successfully cloned and sequenced the complete gene cluster for halstoctacosanolide biosynthesis, and revealed that seven ORFs encoded type I 49 PKS and two ORFs encoded P450 monooxygenase in this hls cluster. Involvement of the hls gene cluster in halstoctacosanolide biosynthesis was confirmed by the gene disruption of hlsH and I. Furthermore, we successfully generated a new halstoctacosanolide analogue through gene manipulations.
Experimental
General
Optical rotation was measured with a JASCO DIP-360 spectrometer. Mass spectra were obtained on a JEOL JMS-700 in the positive FAB mode using 3-nitrobenzyl alcohol as a matrix. UV and IR spectra were recorded on a Shimadzu UV-160A spectrophotometer and Horiba FT-710 spectrometer, respectively. NMR spectra were obtained by a JEOL LA-400 and/or a Bruker DRX-500 spectrometers. 
DNA Manipulations and Southern Hybridization
Isolation of S. halstedii genomic DNA and construction of its genome library were described previously [17] . Purification of plasmids from E. coli was carried out by GFX micro Plasmid Prep Kit (Amersham Biosciences). General DNA manipulations in E. coli were performed according to standard protocols [18] . To proceed gene walking, Southern hybridization was carried out using a probe derived from the digested DNA fragment existing most downstream of the isolated cosmid. Labeling of DNA with dioxigenin-dUDP and detection of the hybridized DNA were carried out using DIG DNA Labeling Kit and Detection Kit (Roche Diagnostics).
Sequencing and Sequence Analysis
DNA sequencing was performed on double-stranded DNA templates by dideoxynucleotide chain-termination method with a Model 4000-1 (Li-COR) and ThermoSequencase Cycle Sequencing Kit, and a part of these was ordered to Hitachi High-Technologies. DNA sequences were analyzed with the Align-IR (LI-COR) and the DNASIS program (Hitachi Software Engineering). Protein sequence homology searches of databases were carried out using the BLAST and the FASTA programs.
Gene Disruption
To disrupt the hlsH gene, the plasmid, named pWHM-dH, was prepared as follows. Firstly the BamHI-BglII fragment (ca. 4.5 kb) around the hlsH gene was subcloned into the BamHI site of pBluescript II SK(ϩ), and then the apramycin resistant cassette, aac3(VI) [19] , was inserted into the AatII site of the hlsH gene of the resulting plasmid.
Finally the HindIII-XbaI fragment (ca. 6 kb) containing the resulting disrupted hlsH gene was subcloned into HindIIIXbaI site of pWHM3. In the case of disruption of the hlsI gene, the plasmid, named pWHM-dI, was prepared as follows. The SphI fragment (ca. 5 kb) involving the hlsI gene was subcloned into SphI site of PUC119, whose BamHI site had been removed, and then the apramycin resistant cassette was inserted into the BamHI site of the hlsI gene of the resulting plasmid. Finally the SphI fragment (ca. 6 kb) containing the resulting disrupted hlsI gene was subcloned into SphI site of pWHM3. The resulting pWHM-dH and -dI were separately introduced into protoplasts of S. lividans TK24, and the plasmids were isolated from S. lividans TK24. The plasmids were separately purified by a standard CsCl-ethidium bromide gradient centrifugation method [15] . Each pure plasmid was introduced into protoplasts of S. halstedii. For homologous recombination, the appropriate transformants were sporulated on R5 agar plates for 20 days. After singlation, the colonies showing the proper phenotype, thiostrepton-sensitive and apramycin-resistant, were selected.
Isolation and Purification of Halstoctacosanolide C
The fermentation broth (1.5 liters) of the hlsI mutant was centrifuged to obtain a mycelium cake and supernatant. The mycelium cake was extracted with acetone (500 ml). The extract was filtered through a pad of Celite and evaporated to give an aqueous suspension. The suspension, after being adjusted to pH 10, was extracted three times with ethyl acetate. The combined organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. The supernatant was also extracted three times with ethyl acetate. The combined organic layer was washed with brine, dried over MgSO 4 , and concentrated in vacuo. Then, the crude residues thus obtained were combined and subjected to a flash silica gel column chromatography, which was eluted with 80% ethyl acetate in hexane to afford halstoctacosanolide C (42 mg). 
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